Thermo Fisher Scientific Inc. (0R0H.L)
USD 413.48
(-6.98%)
USD 413.48
(-6.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 26.84 Billion USD | 3.37% |
| 2022 | 25.96 Billion USD | -14.57% |
| 2021 | 30.39 Billion USD | 166.37% |
| 2020 | 11.41 Billion USD | -25.68% |
| 2019 | 15.35 Billion USD | -9.08% |
| 2018 | 16.88 Billion USD | -14.16% |
| 2017 | 19.67 Billion USD | 24.18% |
| 2016 | 15.84 Billion USD | 31.2% |
| 2015 | 12.07 Billion USD | -8.67% |
| 2014 | 13.22 Billion USD | 183.62% |
| 2013 | 4.66 Billion USD | -26.23% |
| 2012 | 6.31 Billion USD | 5.11% |
| 2011 | 6.01 Billion USD | 841.0% |
| 2010 | -811.3 Million USD | -231.0% |
| 2009 | 619.3 Million USD | -20.38% |
| 2008 | 777.8 Million USD | -50.46% |
| 2007 | 1.57 Billion USD | -21.36% |
| 2006 | 1.99 Billion USD | 419.34% |
| 2005 | 384.44 Million USD | 548.07% |
| 2004 | -85.79 Million USD | -201.88% |
| 2003 | -28.42 Million USD | -104.76% |
| 2002 | 596.78 Million USD | 22.04% |
| 2001 | 489 Million USD | -55.67% |
| 2000 | 1.1 Billion USD | -21.05% |
| 1999 | 1.39 Billion USD | -20.76% |
| 1998 | 1.76 Billion USD | 32.96% |
| 1997 | 1.32 Billion USD | 2.79% |
| 1996 | 1.29 Billion USD | 69.74% |
| 1995 | 760 Million USD | 1.33% |
| 1994 | 750 Million USD | 103.97% |
| 1993 | 367.7 Million USD | 12.93% |
| 1992 | 325.6 Million USD | 152.6% |
| 1991 | 128.9 Million USD | 30.33% |
| 1990 | 98.9 Million USD | -6.43% |
| 1989 | 105.7 Million USD | 351.71% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 30.66 Billion USD | 8.29% |
| 2024 Q1 | 30.1 Billion USD | 12.15% |
| 2024 Q2 | 28.32 Billion USD | -5.92% |
| 2023 Q1 | 31.77 Billion USD | 22.38% |
| 2023 Q3 | 29.13 Billion USD | -5.64% |
| 2023 FY | 26.84 Billion USD | 3.37% |
| 2023 Q2 | 30.87 Billion USD | -2.83% |
| 2023 Q4 | 26.84 Billion USD | -7.87% |
| 2022 Q1 | 30.5 Billion USD | 0.36% |
| 2022 FY | 25.96 Billion USD | -14.57% |
| 2022 Q4 | 25.96 Billion USD | -1.06% |
| 2022 Q3 | 26.24 Billion USD | -7.51% |
| 2022 Q2 | 28.37 Billion USD | -6.99% |
| 2021 Q3 | 9.68 Billion USD | -17.65% |
| 2021 Q4 | 30.39 Billion USD | 213.98% |
| 2021 Q1 | 13.06 Billion USD | 14.48% |
| 2021 FY | 30.39 Billion USD | 166.37% |
| 2021 Q2 | 11.75 Billion USD | -10.01% |
| 2020 Q2 | 15.49 Billion USD | -8.79% |
| 2020 Q3 | 13.55 Billion USD | -12.53% |
| 2020 Q4 | 11.41 Billion USD | -15.81% |
| 2020 FY | 11.41 Billion USD | -25.68% |
| 2020 Q1 | 16.98 Billion USD | 10.65% |
| 2019 Q4 | 15.35 Billion USD | -2.71% |
| 2019 FY | 15.35 Billion USD | -9.08% |
| 2019 Q1 | 17.04 Billion USD | 0.92% |
| 2019 Q3 | 15.78 Billion USD | -5.8% |
| 2019 Q2 | 16.75 Billion USD | -1.7% |
| 2018 Q3 | 17.67 Billion USD | -4.37% |
| 2018 Q4 | 16.88 Billion USD | -4.46% |
| 2018 FY | 16.88 Billion USD | -14.16% |
| 2018 Q1 | 19.98 Billion USD | 1.59% |
| 2018 Q2 | 18.48 Billion USD | -7.52% |
| 2017 Q1 | 16.35 Billion USD | 3.25% |
| 2017 FY | 19.67 Billion USD | 24.18% |
| 2017 Q3 | 21.25 Billion USD | 31.3% |
| 2017 Q4 | 19.67 Billion USD | -7.43% |
| 2017 Q2 | 16.18 Billion USD | -1.05% |
| 2016 Q1 | 14.2 Billion USD | 17.68% |
| 2016 Q2 | 13.48 Billion USD | -5.1% |
| 2016 Q3 | 16.94 Billion USD | 25.64% |
| 2016 Q4 | 15.84 Billion USD | -6.5% |
| 2016 FY | 15.84 Billion USD | 31.2% |
| 2015 Q3 | 12.8 Billion USD | -3.37% |
| 2015 FY | 12.07 Billion USD | -8.67% |
| 2015 Q1 | 13.99 Billion USD | 5.84% |
| 2015 Q2 | 13.25 Billion USD | -5.27% |
| 2015 Q4 | 12.07 Billion USD | -5.73% |
| 2014 Q4 | 13.22 Billion USD | -5.18% |
| 2014 Q3 | 13.94 Billion USD | -7.0% |
| 2014 Q2 | 14.99 Billion USD | -5.5% |
| 2014 Q1 | 15.86 Billion USD | 240.36% |
| 2014 FY | 13.22 Billion USD | 183.62% |
| 2013 Q1 | 6.11 Billion USD | -3.23% |
| 2013 Q4 | 4.66 Billion USD | -11.48% |
| 2013 Q3 | 5.26 Billion USD | -7.7% |
| 2013 Q2 | 5.7 Billion USD | -6.69% |
| 2013 FY | 4.66 Billion USD | -26.23% |
| 2012 FY | 6.31 Billion USD | 5.11% |
| 2012 Q4 | 6.31 Billion USD | -4.84% |
| 2012 Q3 | 6.64 Billion USD | 14.49% |
| 2012 Q1 | 5.88 Billion USD | -2.08% |
| 2012 Q2 | 5.79 Billion USD | -1.48% |
| 2011 FY | 6.01 Billion USD | 841.0% |
| 2011 Q4 | 6.01 Billion USD | -3.71% |
| 2011 Q3 | 6.24 Billion USD | 133.74% |
| 2011 Q2 | 2.67 Billion USD | 76.73% |
| 2011 Q1 | 1.51 Billion USD | 23.89% |
| 2010 Q1 | 647.4 Million USD | 4.54% |
| 2010 FY | -811.3 Million USD | -231.0% |
| 2010 Q3 | -822.5 Million USD | -198.93% |
| 2010 Q4 | 1.22 Billion USD | 248.33% |
| 2010 Q2 | 831.4 Million USD | 28.42% |
| 2009 FY | 619.3 Million USD | -20.38% |
| 2009 Q2 | 627.1 Million USD | 30.92% |
| 2009 Q1 | 479 Million USD | -38.42% |
| 2009 Q4 | 619.3 Million USD | 114.29% |
| 2009 Q3 | 289 Million USD | -53.91% |
| 2008 Q2 | 1.18 Billion USD | -19.13% |
| 2008 Q1 | 1.46 Billion USD | -6.84% |
| 2008 FY | 777.8 Million USD | -50.46% |
| 2008 Q3 | 941.5 Million USD | -20.41% |
| 2008 Q4 | 777.8 Million USD | -17.39% |
| 2007 Q2 | 1.25 Billion USD | -25.47% |
| 2007 Q1 | 1.67 Billion USD | -15.91% |
| 2007 FY | 1.57 Billion USD | -21.36% |
| 2007 Q3 | 1.36 Billion USD | 9.48% |
| 2007 Q4 | 1.57 Billion USD | 14.61% |
| 2006 FY | 1.99 Billion USD | 419.34% |
| 2006 Q3 | 380.58 Million USD | -15.29% |
| 2006 Q1 | 329.66 Million USD | -14.25% |
| 2006 Q2 | 449.28 Million USD | 36.29% |
| 2006 Q4 | 1.99 Billion USD | 424.61% |
| 2005 Q4 | 384.44 Million USD | -13.81% |
| 2005 Q1 | -125.14 Million USD | -45.86% |
| 2005 FY | 384.44 Million USD | 548.07% |
| 2005 Q2 | 541.45 Million USD | 532.66% |
| 2005 Q3 | 446.05 Million USD | -17.62% |
| 2004 Q2 | -47.01 Million USD | 41.24% |
| 2004 Q1 | -80 Million USD | -181.49% |
| 2004 Q3 | -91.84 Million USD | -95.37% |
| 2004 FY | -85.79 Million USD | -201.88% |
| 2004 Q4 | -85.79 Million USD | 6.59% |
| 2003 FY | -28.42 Million USD | -104.76% |
| 2003 Q1 | 432.83 Million USD | -27.47% |
| 2003 Q2 | 190.93 Million USD | -55.89% |
| 2003 Q3 | 47.46 Million USD | -75.14% |
| 2003 Q4 | -28.42 Million USD | -159.88% |
| 2002 Q1 | 832 Million USD | -13.15% |
| 2002 Q2 | 873 Million USD | 4.93% |
| 2002 Q4 | 596.78 Million USD | -26.23% |
| 2002 Q3 | 809 Million USD | -7.33% |
| 2002 FY | 596.78 Million USD | 22.04% |
| 2001 FY | 489 Million USD | -55.67% |
| 2001 Q4 | 958 Million USD | -13.93% |
| 2001 Q3 | 1.11 Billion USD | 5.17% |
| 2001 Q2 | 1.05 Billion USD | -16.46% |
| 2001 Q1 | 1.26 Billion USD | 12.5% |
| 2000 Q4 | 1.12 Billion USD | -16.85% |
| 2000 Q1 | 1.3 Billion USD | -18.53% |
| 2000 Q2 | 1.43 Billion USD | 9.95% |
| 2000 Q3 | 1.35 Billion USD | -5.69% |
| 2000 FY | 1.1 Billion USD | -21.05% |
| 1999 Q2 | 1.76 Billion USD | -0.51% |
| 1999 Q4 | 1.6 Billion USD | -11.19% |
| 1999 Q3 | 1.8 Billion USD | 2.04% |
| 1999 Q1 | 1.77 Billion USD | 8.35% |
| 1999 FY | 1.39 Billion USD | -20.76% |
| 1998 Q2 | 1.45 Billion USD | -4.08% |
| 1998 Q3 | 1.6 Billion USD | 9.81% |
| 1998 Q1 | 1.52 Billion USD | 14.63% |
| 1998 FY | 1.76 Billion USD | 32.96% |
| 1998 Q4 | 1.64 Billion USD | 2.5% |
| 1997 Q2 | 1.36 Billion USD | -5.82% |
| 1997 Q3 | 1.45 Billion USD | 6.62% |
| 1997 Q4 | 1.32 Billion USD | -8.55% |
| 1997 FY | 1.32 Billion USD | 2.79% |
| 1997 Q1 | 1.44 Billion USD | 11.94% |
| 1996 Q3 | 1.05 Billion USD | -16.95% |
| 1996 Q4 | 1.29 Billion USD | 21.93% |
| 1996 FY | 1.29 Billion USD | 69.74% |
| 1996 Q1 | 1 Billion USD | 31.42% |
| 1996 Q2 | 1.27 Billion USD | 26.39% |
| 1995 Q3 | 733.9 Million USD | 14.14% |
| 1995 Q1 | 713 Million USD | -4.93% |
| 1995 Q2 | 643 Million USD | -9.82% |
| 1995 Q4 | 767 Million USD | 4.51% |
| 1995 FY | 760 Million USD | 1.33% |
| 1994 FY | 750 Million USD | 103.97% |
| 1994 Q3 | 819 Million USD | -8.08% |
| 1994 Q4 | 750 Million USD | -8.42% |
| 1994 Q2 | 891 Million USD | 51.27% |
| 1994 Q1 | 589 Million USD | 60.18% |
| 1993 Q2 | 416.1 Million USD | 3.84% |
| 1993 Q1 | 400.7 Million USD | 23.07% |
| 1993 Q4 | 367.7 Million USD | 76.95% |
| 1993 FY | 367.7 Million USD | 12.93% |
| 1993 Q3 | 207.8 Million USD | -50.06% |
| 1992 Q1 | 106.9 Million USD | -17.07% |
| 1992 Q2 | 107 Million USD | 0.09% |
| 1992 Q4 | 325.6 Million USD | -0.67% |
| 1992 FY | 325.6 Million USD | 152.6% |
| 1992 Q3 | 327.8 Million USD | 206.36% |
| 1991 Q1 | 148.1 Million USD | 49.75% |
| 1991 Q3 | 159.1 Million USD | -1.79% |
| 1991 Q4 | 128.9 Million USD | -18.98% |
| 1991 FY | 128.9 Million USD | 30.33% |
| 1991 Q2 | 162 Million USD | 9.39% |
| 1990 Q3 | 143.5 Million USD | 0.49% |
| 1990 FY | 98.9 Million USD | -6.43% |
| 1990 Q1 | 100.3 Million USD | -5.11% |
| 1990 Q2 | 142.8 Million USD | 42.37% |
| 1990 Q4 | 98.9 Million USD | -31.08% |
| 1989 FY | 105.7 Million USD | 351.71% |
| 1989 Q3 | 129.7 Million USD | 0.0% |
| 1989 Q4 | 105.7 Million USD | -18.5% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 26170.655% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 86078.794% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -13451.107% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -84077.513% |
| bluebird bio, Inc. | 108.57 Million USD | -24621.15% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 297792.99% |
| Imunon, Inc. | -4.69 Million USD | 571252.176% |
| Editas Medicine, Inc. | -87.11 Million USD | 30909.495% |
| IQVIA Holdings Inc. | 12.85 Billion USD | -108.79% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | -1179.337% |
| Myriad Genetics, Inc. | 88.1 Million USD | -30365.38% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -15038.184% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 80154.881% |
| Verastem, Inc. | -37.27 Million USD | 72099.571% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | -225.926% |
| Waters Corporation | 1.96 Billion USD | -1269.083% |
| Biogen Inc. | 6.28 Billion USD | -326.824% |
| Nektar Therapeutics | 210.24 Million USD | -12666.362% |
| Perrigo Company plc | 3.32 Billion USD | -707.923% |
| Dynavax Technologies Corporation | 106.63 Million USD | -25069.972% |
| Illumina, Inc. | 1.21 Billion USD | -2110.873% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -385085.236% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 23667.013% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -18400.648% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -373352.066% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -6986.506% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 378128.169% |
| Evolus, Inc. | 63.7 Million USD | -42029.717% |
| Adicet Bio, Inc. | -142 Million USD | 19000.344% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 73026.856% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 99140.59% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -5751.332% |
| FibroGen, Inc. | 56.76 Million USD | -47180.991% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -2244.105% |
| OPKO Health, Inc. | 230.68 Million USD | -11535.014% |
| Homology Medicines, Inc. | 18.43 Million USD | -145476.829% |
| Geron Corporation | 14.76 Million USD | -181730.499% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -1593.026% |
| Exelixis, Inc. | -73.05 Million USD | 36841.958% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 49569.183% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 17872.01% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 24192.925% |
| Zoetis Inc. | 4.76 Billion USD | -463.629% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 13532.022% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 266607.795% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 380.639% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 184288.855% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -2445.83% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -2671.645% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 19922.747% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -1843.691% |
| Blueprint Medicines Corporation | 702.83 Million USD | -3718.814% |
| Insmed Incorporated | 721.62 Million USD | -3619.409% |
| TG Therapeutics, Inc. | 17.86 Million USD | -150163.128% |
| Incyte Corporation | -3.17 Billion USD | 945.331% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -3404.832% |